Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Mar-Apr;2(2):137-47.
doi: 10.4161/mabs.2.2.11271.

Certolizumab pegol

Niti Goel  1 , Sue Stephens
Affiliations
Review

Certolizumab pegol

Niti Goel et al. MAbs. 2010 Mar-Apr.

Abstract

Certolizumab pegol (Cimzia(®)) is currently the only PEGylated anti-TNFα biologic approved for the treatment of rheumatoid arthritis and Crohn disease. The product, developed by UCB, is a humanized antigen-binding fragment (Fab') of a monoclonal antibody that has been conjugated to polyethylene glycol. Certolizumab pegol was approved as a treatment for rheumatoid arthritis in the EU, US and Canada in 2009, and as a treatment for Crohn disease in Switzerland in 2007 and the US in 2008. Certolizumab pegol is entering into an increasingly competitive marketplace, especially in rheumatoid arthritis, but clinical data demonstrate benefits across a range of clinical, radiographic and patient reported outcomes.

PubMed Disclaimer

References

    1. Stakeholder Insight: Rheumatoid arthritis, biologics battle up the treatment algorithm. Data monitor. 2006:1–181.
    1. Felfmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440. - PubMed
    1. Tracy D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumour necrosis mechanism of action: a comprehensive review. Pharmacol Ther. 2008;117:244–279. - PubMed
    1. Redlich K, Schett G, Steiner G, Hayer S, Wagner EF, Smolen JS. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum. 2003;48:3308–3319. - PubMed
    1. Van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when eternacept (Enbrel) has failed or vice vera: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann Rheum Dis. 2003;62:1195–1198. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources